101 4 Diabetes-tuberculosis comorbidity in a low-income setting Tuberculosis treatment outcomes Intermediate treatment outcomes Of 216 (59%) participants with data for month two follow-up sputum, 214 (99%) had a negative sputum result, while 229 out of 232 (98.7%) had a negative sputum at the end of treatment. Final treatment outcomes All but one patient had a TB treatment outcome assigned: completed (N=150, 40.7%), cured (N=126, 34.2%), died (N=34, 9.2%), loss to follow-up (N=19, 5.2%), transferred out (N=13, 3.5%), active (N=6, 1.6%), re-initiated (N=6, 1.6%), DRTB on treatment (N=3, 0.8%) and stopped treatment (N=2, 0.5%) (Supplementary file 3). The median treatment duration for all patients was 6.2 months (SD: 5.6, 6.8). Overall, 276 patients (75.4%) had a favourable TB treatment outcome, with slightly more males than females (51% vs. 49%). More males (N=59, 66%) had an unfavourable TB treatment outcome (N=90, 24.6%) compared to females (p=0.020), and the majority of those with an unfavourable outcome (N=82, 91%) were aged ≥25 years. Proportionately, 19%, 21%, 20%, 27%, and 44% aged <25 years, 25 - 34 years, 35 – 44 years, 45 – 54 years and ≥55 years had an unfavourable outcome, respectively, and those with an unfavourable outcome were significantly older than those with a favourable outcome (p=0.003). Thirty-four patients (9.2%) died, and more than half were males (N=20, 59%). More males were lost to follow-up (N=16, 84%), were re-initiated for any reason (N=5, 83%) and were transferred out (N=9, 69%) compared to females. For the patients who died, 14 (41.2%) died <1 month after commencing treatment, 6 (17.6%) died within 1 – 2 months, 10 (29.4%) died within 2 – 3 months, and 4 (11.8%) died >3 months after commencing treatment. Blood glucose and Tuberculosis treatment outcome The median difference in blood glucose between patients with a favourable outcome and those with an unfavourable outcome was 0.1 mmol/l (p=0.7028) at baseline, 0.2 mmol/l (p=0.407) at the second-month visit and 0.2 mmol/l (p=0.266) at the fifth-month visit. After controlling for age, sex, and baseline HIV status, elevated blood glucose did not predict an unfavourable outcome (OR 1.44; 95% CI: 0.61, 3.40; p=0.404). More than two-thirds (N=19, 67.8%) of patients with elevated baseline blood glucose had a favourable TB treatment outcome. Five (17.9%) died, 2 (7.1%) were lost to follow-up, and one each stopped treatment and was transferred out.
RkJQdWJsaXNoZXIy MTk4NDMw